Our Company Strategy & Mission Leadership Our Board Partnering Opportunities Out-Licensing Opportunities Contact Our Pipeline Clinical Trials Disease Information Innovation Engine Akeso Partnership Overview Ivonescimab (SMT112) Overview Therapeutic Areas News Center Media Resources Press Releases Investor Center Investor Center Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Board of Directors Diversity Matrix Shareholder Meetings Summit Presentations Career Opportunities
Press Releases Our latest press releases are available to read here Press Releases Date Range Explore Search Press Releases / 18 Jul 2022 Summit Therapeutics Announces Commencement of $100 Million Rights Offering Press Releases / 14 Jul 2022 Summit Therapeutics Provides Update on Ridinilazole Press Releases / 22 Jun 2022 Summit Therapeutics Announces $100 Million Rights Offering Press Releases / 03 Jun 2022 Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting Press Releases / 01 Jun 2022 Summit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer Press Releases / 11 May 2022 Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022 Press Releases / 17 Mar 2022 Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021 Press Releases / 09 Feb 2022 Summit Therapeutics Announces Postponement of Its Planned Rights Offering Press Releases / 25 Jan 2022 Summit Therapeutics Announces Rights Offering Press Releases / 10 Jan 2022 Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference Press Releases / 05 Jan 2022 Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference Press Releases / 20 Dec 2021 Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection << 1 2 3 … 31 32 >>
Press Releases / 18 Jul 2022 Summit Therapeutics Announces Commencement of $100 Million Rights Offering Press Releases / 14 Jul 2022 Summit Therapeutics Provides Update on Ridinilazole Press Releases / 22 Jun 2022 Summit Therapeutics Announces $100 Million Rights Offering Press Releases / 03 Jun 2022 Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting Press Releases / 01 Jun 2022 Summit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer Press Releases / 11 May 2022 Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022 Press Releases / 17 Mar 2022 Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021 Press Releases / 09 Feb 2022 Summit Therapeutics Announces Postponement of Its Planned Rights Offering Press Releases / 25 Jan 2022 Summit Therapeutics Announces Rights Offering Press Releases / 10 Jan 2022 Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference Press Releases / 05 Jan 2022 Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference Press Releases / 20 Dec 2021 Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
Press Releases / 18 Jul 2022 Summit Therapeutics Announces Commencement of $100 Million Rights Offering
Press Releases / 11 May 2022 Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
Press Releases / 17 Mar 2022 Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021
Press Releases / 09 Feb 2022 Summit Therapeutics Announces Postponement of Its Planned Rights Offering
Press Releases / 10 Jan 2022 Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
Press Releases / 05 Jan 2022 Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
Press Releases / 20 Dec 2021 Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
Website Cookies This website uses cookies: Please see our Privacy Policy to understand how we use cookies. Okay, thanks